A Trial of HR19042 Capsule in Healthy Chinese Subjects
Safety and Pharmacokinetics of HR19042 Capsule After Single Administration in Healthy Chinese Subjects
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
A PHASE1 clinical study on Primary IgA Nephropathy, this trial is completed. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 4 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
-
Jun 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .